Drugs / Fluzone Quadrivalent Influenza Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03546192 | Jun → Jul 2015 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluzone Quadrivalent Influenza Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03546192 ↗ |
| Modality | Vaccine | “An inactivated split-virion quadrivalent influenza vaccine” PMID 28933626 ↗ Oct 2017 |
| Route | Intramuscular | “received one 0.5-mL dose of Fluzone Quadrivalent influenza vaccine, intramuscularly, at Day 0.” NCT03546192 ↗ |